Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Catheter Ablation | 47 | 2023 | 2788 | 4.650 |
Why?
|
Portasystemic Shunt, Transjugular Intrahepatic | 8 | 2023 | 95 | 4.100 |
Why?
|
Radiology, Interventional | 12 | 2024 | 485 | 3.190 |
Why?
|
Liver Neoplasms | 23 | 2024 | 4353 | 2.650 |
Why?
|
Radiography, Interventional | 11 | 2023 | 1129 | 2.630 |
Why?
|
Mammary Neoplasms, Experimental | 17 | 2018 | 498 | 2.530 |
Why?
|
Ablation Techniques | 9 | 2021 | 254 | 2.310 |
Why?
|
Cryosurgery | 5 | 2024 | 479 | 2.270 |
Why?
|
Carcinoma, Hepatocellular | 17 | 2024 | 2329 | 2.140 |
Why?
|
Doxorubicin | 18 | 2016 | 2230 | 2.040 |
Why?
|
Chemoembolization, Therapeutic | 6 | 2023 | 129 | 1.900 |
Why?
|
Embolization, Therapeutic | 6 | 2021 | 1403 | 1.710 |
Why?
|
Antibiotics, Antineoplastic | 6 | 2016 | 679 | 1.610 |
Why?
|
Bile Duct Neoplasms | 4 | 2021 | 626 | 1.430 |
Why?
|
Hepatic Encephalopathy | 2 | 2022 | 143 | 1.400 |
Why?
|
Portal Vein | 6 | 2023 | 435 | 1.360 |
Why?
|
Rats, Inbred F344 | 20 | 2024 | 822 | 1.350 |
Why?
|
Liver | 20 | 2024 | 7562 | 1.340 |
Why?
|
Venous Thrombosis | 6 | 2023 | 1327 | 1.330 |
Why?
|
Esophageal and Gastric Varices | 3 | 2023 | 215 | 1.320 |
Why?
|
Yttrium Radioisotopes | 3 | 2024 | 116 | 1.170 |
Why?
|
Catheterization, Peripheral | 2 | 2020 | 349 | 1.040 |
Why?
|
Hyperthermia, Induced | 8 | 2016 | 415 | 1.040 |
Why?
|
End Stage Liver Disease | 2 | 2022 | 369 | 1.040 |
Why?
|
Microspheres | 3 | 2024 | 773 | 1.010 |
Why?
|
Liver Transplantation | 4 | 2023 | 2412 | 0.980 |
Why?
|
Ultrasonography, Interventional | 9 | 2024 | 1531 | 0.980 |
Why?
|
Liver Neoplasms, Experimental | 5 | 2019 | 190 | 0.950 |
Why?
|
Liposomes | 13 | 2023 | 788 | 0.940 |
Why?
|
Cholangiocarcinoma | 2 | 2021 | 578 | 0.920 |
Why?
|
Catheterization, Central Venous | 3 | 2024 | 539 | 0.890 |
Why?
|
Hepatectomy | 2 | 2019 | 589 | 0.890 |
Why?
|
Neoplasms, Multiple Primary | 2 | 2023 | 587 | 0.840 |
Why?
|
Hand | 4 | 2024 | 909 | 0.820 |
Why?
|
Evoked Potentials, Somatosensory | 1 | 2024 | 240 | 0.810 |
Why?
|
Surgery, Computer-Assisted | 5 | 2014 | 993 | 0.810 |
Why?
|
Needles | 2 | 2024 | 460 | 0.760 |
Why?
|
Clinical Competence | 7 | 2024 | 4863 | 0.760 |
Why?
|
Quercetin | 4 | 2016 | 97 | 0.730 |
Why?
|
Chemotherapy, Adjuvant | 13 | 2017 | 3537 | 0.730 |
Why?
|
Evoked Potentials, Motor | 1 | 2024 | 463 | 0.730 |
Why?
|
Splenic Artery | 1 | 2021 | 55 | 0.710 |
Why?
|
Transurethral Resection of Prostate | 1 | 2021 | 76 | 0.700 |
Why?
|
Patient Readmission | 3 | 2020 | 3286 | 0.690 |
Why?
|
Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2023 | 891 | 0.680 |
Why?
|
Neoplasms | 14 | 2021 | 22340 | 0.660 |
Why?
|
Electromagnetic Phenomena | 1 | 2020 | 160 | 0.660 |
Why?
|
Venereal Tumors, Veterinary | 3 | 2004 | 8 | 0.650 |
Why?
|
Splenic Vein | 1 | 2019 | 30 | 0.650 |
Why?
|
Hepatic Artery | 2 | 2018 | 231 | 0.650 |
Why?
|
Pericardiectomy | 1 | 2019 | 46 | 0.650 |
Why?
|
Radial Artery | 1 | 2020 | 189 | 0.630 |
Why?
|
Cholangitis, Sclerosing | 1 | 2021 | 177 | 0.630 |
Why?
|
Microwaves | 2 | 2016 | 182 | 0.590 |
Why?
|
Motor Skills | 1 | 2020 | 516 | 0.570 |
Why?
|
Health Literacy | 1 | 2023 | 464 | 0.570 |
Why?
|
Drainage | 3 | 2022 | 1179 | 0.570 |
Why?
|
Adenocarcinoma | 9 | 2017 | 6364 | 0.560 |
Why?
|
After-Hours Care | 1 | 2018 | 103 | 0.560 |
Why?
|
Heat-Shock Proteins | 4 | 2018 | 791 | 0.560 |
Why?
|
Catheters | 2 | 2022 | 426 | 0.560 |
Why?
|
Pericardial Effusion | 1 | 2019 | 246 | 0.560 |
Why?
|
Common Bile Duct Diseases | 1 | 2017 | 36 | 0.560 |
Why?
|
Cholestasis, Extrahepatic | 1 | 2017 | 52 | 0.560 |
Why?
|
Prostatic Hyperplasia | 1 | 2021 | 515 | 0.550 |
Why?
|
Terminology as Topic | 2 | 2014 | 1534 | 0.550 |
Why?
|
HSP70 Heat-Shock Proteins | 3 | 2016 | 393 | 0.540 |
Why?
|
STAT3 Transcription Factor | 2 | 2019 | 870 | 0.540 |
Why?
|
Benchmarking | 1 | 2023 | 1052 | 0.530 |
Why?
|
Foot Diseases | 1 | 2017 | 147 | 0.520 |
Why?
|
Nickel | 1 | 2017 | 126 | 0.520 |
Why?
|
Ampulla of Vater | 1 | 2017 | 150 | 0.520 |
Why?
|
Neoplasm Seeding | 1 | 2016 | 85 | 0.520 |
Why?
|
Fibroma | 1 | 2017 | 197 | 0.510 |
Why?
|
Nanoparticles | 3 | 2016 | 1964 | 0.500 |
Why?
|
Retrospective Studies | 43 | 2024 | 81514 | 0.500 |
Why?
|
Treatment Outcome | 32 | 2024 | 65188 | 0.490 |
Why?
|
Graft Occlusion, Vascular | 1 | 2018 | 540 | 0.480 |
Why?
|
Rats | 22 | 2024 | 23707 | 0.480 |
Why?
|
Gastrointestinal Hemorrhage | 3 | 2023 | 1127 | 0.470 |
Why?
|
Sarcoma, Experimental | 2 | 2005 | 116 | 0.470 |
Why?
|
Angioplasty, Balloon | 1 | 2018 | 608 | 0.460 |
Why?
|
Kidney Neoplasms | 5 | 2019 | 4274 | 0.450 |
Why?
|
Cyclooxygenase 2 Inhibitors | 1 | 2016 | 318 | 0.450 |
Why?
|
Electric Conductivity | 6 | 2013 | 403 | 0.450 |
Why?
|
Hepatocyte Growth Factor | 4 | 2022 | 268 | 0.440 |
Why?
|
Telemedicine | 2 | 2022 | 3105 | 0.440 |
Why?
|
Angioplasty | 1 | 2016 | 352 | 0.430 |
Why?
|
Postoperative Complications | 5 | 2021 | 15747 | 0.430 |
Why?
|
Device Removal | 2 | 2023 | 646 | 0.420 |
Why?
|
Humans | 95 | 2024 | 765968 | 0.420 |
Why?
|
Electroporation | 4 | 2016 | 238 | 0.420 |
Why?
|
Microvessels | 2 | 2017 | 591 | 0.410 |
Why?
|
Sulfones | 1 | 2015 | 447 | 0.410 |
Why?
|
Liver Diseases | 1 | 2021 | 1303 | 0.400 |
Why?
|
Female | 69 | 2024 | 396112 | 0.390 |
Why?
|
Middle Aged | 45 | 2024 | 223009 | 0.390 |
Why?
|
Pneumothorax | 3 | 2021 | 392 | 0.390 |
Why?
|
Combined Modality Therapy | 16 | 2018 | 8529 | 0.380 |
Why?
|
Male | 54 | 2024 | 363698 | 0.380 |
Why?
|
Feasibility Studies | 5 | 2023 | 5302 | 0.370 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2014 | 618 | 0.360 |
Why?
|
Micelles | 3 | 2016 | 188 | 0.350 |
Why?
|
Boronic Acids | 1 | 2014 | 916 | 0.350 |
Why?
|
Necrosis | 7 | 2022 | 1617 | 0.340 |
Why?
|
Thrombolytic Therapy | 1 | 2019 | 2059 | 0.340 |
Why?
|
Thermal Conductivity | 2 | 2008 | 15 | 0.330 |
Why?
|
Animals | 48 | 2024 | 168764 | 0.330 |
Why?
|
Neoplasm Transplantation | 7 | 2017 | 2014 | 0.320 |
Why?
|
Up-Regulation | 2 | 2017 | 4137 | 0.320 |
Why?
|
Ventricular Function, Left | 1 | 2022 | 3928 | 0.310 |
Why?
|
Pyrazines | 1 | 2014 | 1204 | 0.310 |
Why?
|
Thrombosis | 1 | 2022 | 2949 | 0.310 |
Why?
|
Physicians | 2 | 2023 | 4588 | 0.310 |
Why?
|
Disease Models, Animal | 13 | 2023 | 18293 | 0.310 |
Why?
|
Varicose Veins | 2 | 2023 | 158 | 0.310 |
Why?
|
Research Design | 2 | 2014 | 6209 | 0.300 |
Why?
|
Liver Diseases, Parasitic | 1 | 2008 | 9 | 0.300 |
Why?
|
Stents | 2 | 2018 | 3213 | 0.300 |
Why?
|
Internship and Residency | 3 | 2023 | 5946 | 0.300 |
Why?
|
Patient Care Planning | 1 | 2013 | 906 | 0.300 |
Why?
|
Liver Cirrhosis | 3 | 2022 | 1959 | 0.290 |
Why?
|
Antineoplastic Agents | 11 | 2015 | 13648 | 0.290 |
Why?
|
Schistosomiasis | 1 | 2008 | 65 | 0.290 |
Why?
|
Vascular Endothelial Growth Factor A | 5 | 2022 | 3513 | 0.290 |
Why?
|
Hypersensitivity | 1 | 2017 | 1168 | 0.280 |
Why?
|
Splenic Diseases | 1 | 2008 | 91 | 0.280 |
Why?
|
Indoles | 1 | 2015 | 1839 | 0.280 |
Why?
|
Heart Failure | 2 | 2022 | 11840 | 0.280 |
Why?
|
Inflammation | 3 | 2016 | 10850 | 0.270 |
Why?
|
Tomography, Spiral Computed | 2 | 2005 | 273 | 0.260 |
Why?
|
Carcinoma, Renal Cell | 2 | 2019 | 3181 | 0.260 |
Why?
|
RNA, Small Interfering | 1 | 2015 | 3421 | 0.260 |
Why?
|
Soft Tissue Neoplasms | 2 | 2005 | 1165 | 0.250 |
Why?
|
Mortality | 1 | 2017 | 2904 | 0.250 |
Why?
|
Aged | 28 | 2024 | 171117 | 0.250 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2023 | 9373 | 0.240 |
Why?
|
Time Factors | 16 | 2024 | 40065 | 0.240 |
Why?
|
Saline Solution, Hypertonic | 2 | 2002 | 116 | 0.230 |
Why?
|
Splenomegaly | 1 | 2005 | 192 | 0.230 |
Why?
|
Prostate | 2 | 2023 | 1755 | 0.220 |
Why?
|
Ambulatory Care | 3 | 2022 | 2778 | 0.220 |
Why?
|
Acetic Acid | 1 | 2003 | 58 | 0.220 |
Why?
|
Tomography, X-Ray Computed | 12 | 2023 | 20659 | 0.210 |
Why?
|
Dog Diseases | 1 | 2003 | 142 | 0.200 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3100 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3223 | 0.200 |
Why?
|
Pelvis | 2 | 2023 | 738 | 0.200 |
Why?
|
Phantoms, Imaging | 3 | 2024 | 2475 | 0.200 |
Why?
|
International Normalized Ratio | 1 | 2024 | 381 | 0.200 |
Why?
|
Thrombin | 1 | 2024 | 602 | 0.190 |
Why?
|
Aneurysm, False | 1 | 2024 | 264 | 0.190 |
Why?
|
Granulocytes | 1 | 2023 | 549 | 0.190 |
Why?
|
Polyethylene Glycols | 4 | 2016 | 1188 | 0.190 |
Why?
|
Suction | 1 | 2022 | 265 | 0.190 |
Why?
|
Hemostatic Techniques | 1 | 2002 | 115 | 0.190 |
Why?
|
Kidney | 5 | 2015 | 7066 | 0.180 |
Why?
|
Thrombectomy | 2 | 2023 | 681 | 0.180 |
Why?
|
Prostatic Neoplasms | 1 | 2023 | 11083 | 0.180 |
Why?
|
Vena Cava Filters | 1 | 2023 | 272 | 0.180 |
Why?
|
Myofibroblasts | 1 | 2022 | 229 | 0.180 |
Why?
|
Lymph Nodes | 3 | 2024 | 3454 | 0.170 |
Why?
|
Pandemics | 1 | 2020 | 8703 | 0.170 |
Why?
|
Tonsillectomy | 2 | 2000 | 284 | 0.170 |
Why?
|
Subcutaneous Tissue | 2 | 2015 | 130 | 0.170 |
Why?
|
Bile Ducts, Intrahepatic | 1 | 2021 | 307 | 0.170 |
Why?
|
Adult | 24 | 2024 | 223044 | 0.170 |
Why?
|
Electrocoagulation | 1 | 2000 | 157 | 0.170 |
Why?
|
Patient Satisfaction | 3 | 2023 | 3475 | 0.160 |
Why?
|
Breast Neoplasms | 3 | 2023 | 21056 | 0.160 |
Why?
|
Gelatin Sponge, Absorbable | 1 | 2019 | 57 | 0.160 |
Why?
|
Lymphatic Vessels | 1 | 2023 | 355 | 0.160 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2023 | 445 | 0.160 |
Why?
|
Punctures | 1 | 2020 | 373 | 0.160 |
Why?
|
Upper Extremity | 1 | 2024 | 682 | 0.160 |
Why?
|
Mice, Inbred C57BL | 7 | 2023 | 22332 | 0.160 |
Why?
|
Uterine Artery Embolization | 1 | 2019 | 62 | 0.160 |
Why?
|
Ascites | 2 | 2023 | 336 | 0.160 |
Why?
|
Living Donors | 1 | 2023 | 645 | 0.150 |
Why?
|
Risk Factors | 12 | 2024 | 74840 | 0.150 |
Why?
|
Peer Review, Health Care | 1 | 2019 | 73 | 0.150 |
Why?
|
Cholangiography | 1 | 2019 | 182 | 0.150 |
Why?
|
Dissection | 1 | 2000 | 299 | 0.150 |
Why?
|
Abscess | 1 | 2022 | 606 | 0.150 |
Why?
|
Consensus | 3 | 2023 | 3202 | 0.150 |
Why?
|
Employee Performance Appraisal | 1 | 2018 | 86 | 0.150 |
Why?
|
Angiography | 1 | 2023 | 1581 | 0.150 |
Why?
|
Aminosalicylic Acids | 1 | 2017 | 37 | 0.150 |
Why?
|
Uterine Hemorrhage | 1 | 2019 | 235 | 0.150 |
Why?
|
Hot Temperature | 5 | 2016 | 1433 | 0.140 |
Why?
|
Neoplasm Metastasis | 3 | 2017 | 4893 | 0.140 |
Why?
|
Macrophages | 3 | 2023 | 5772 | 0.140 |
Why?
|
Abdomen | 1 | 2023 | 1134 | 0.140 |
Why?
|
Intention to Treat Analysis | 1 | 2018 | 416 | 0.140 |
Why?
|
Angiography, Digital Subtraction | 1 | 2018 | 332 | 0.140 |
Why?
|
Lymphedema | 1 | 2023 | 525 | 0.140 |
Why?
|
Magnetic Resonance Imaging | 7 | 2024 | 36532 | 0.140 |
Why?
|
Length of Stay | 4 | 2018 | 6485 | 0.130 |
Why?
|
Benzenesulfonates | 1 | 2017 | 170 | 0.130 |
Why?
|
Patch Tests | 1 | 2017 | 57 | 0.130 |
Why?
|
Radiation Dosage | 2 | 2021 | 1944 | 0.130 |
Why?
|
Professional Practice | 1 | 2018 | 313 | 0.130 |
Why?
|
Neoplasms, Connective Tissue | 1 | 2016 | 36 | 0.130 |
Why?
|
Forkhead Transcription Factors | 1 | 2023 | 1624 | 0.130 |
Why?
|
Arteries | 1 | 2021 | 1118 | 0.130 |
Why?
|
Colorectal Neoplasms | 4 | 2023 | 6942 | 0.130 |
Why?
|
Societies, Medical | 3 | 2023 | 3956 | 0.130 |
Why?
|
Equipment Failure Analysis | 2 | 2016 | 834 | 0.130 |
Why?
|
Interleukin-6 | 2 | 2016 | 3222 | 0.130 |
Why?
|
Lung Neoplasms | 4 | 2023 | 13451 | 0.120 |
Why?
|
Postpartum Hemorrhage | 1 | 2019 | 276 | 0.120 |
Why?
|
Xenograft Model Antitumor Assays | 2 | 2014 | 3608 | 0.120 |
Why?
|
Dogs | 4 | 2004 | 3822 | 0.120 |
Why?
|
Vascular Patency | 1 | 2018 | 912 | 0.120 |
Why?
|
Checklist | 1 | 2022 | 848 | 0.120 |
Why?
|
Constriction, Pathologic | 1 | 2018 | 1105 | 0.120 |
Why?
|
Radiology Department, Hospital | 1 | 2018 | 407 | 0.120 |
Why?
|
Adrenal Cortex Neoplasms | 1 | 2016 | 161 | 0.120 |
Why?
|
Fatal Outcome | 1 | 2019 | 1831 | 0.120 |
Why?
|
Outpatients | 1 | 2022 | 1595 | 0.120 |
Why?
|
Syndrome | 1 | 2021 | 3271 | 0.120 |
Why?
|
Teaching Rounds | 1 | 2019 | 280 | 0.120 |
Why?
|
Vinblastine | 1 | 2016 | 483 | 0.110 |
Why?
|
Cholestasis | 1 | 2017 | 386 | 0.110 |
Why?
|
Hypertrophy | 1 | 2016 | 559 | 0.110 |
Why?
|
Adrenalectomy | 1 | 2016 | 344 | 0.110 |
Why?
|
Ki-67 Antigen | 1 | 2016 | 629 | 0.110 |
Why?
|
Radio Waves | 1 | 2015 | 246 | 0.110 |
Why?
|
Hospital Mortality | 2 | 2018 | 5343 | 0.110 |
Why?
|
Analgesia, Epidural | 1 | 2017 | 337 | 0.110 |
Why?
|
Severity of Illness Index | 2 | 2022 | 15880 | 0.110 |
Why?
|
Prostate-Specific Antigen | 1 | 2023 | 2464 | 0.110 |
Why?
|
Foot | 1 | 2017 | 573 | 0.110 |
Why?
|
Models, Anatomic | 1 | 2017 | 677 | 0.110 |
Why?
|
Oncogene Proteins | 1 | 2017 | 710 | 0.110 |
Why?
|
Radiology Information Systems | 1 | 2018 | 532 | 0.110 |
Why?
|
Random Allocation | 2 | 2016 | 2395 | 0.110 |
Why?
|
Fluoroscopy | 1 | 2017 | 947 | 0.100 |
Why?
|
Equipment Design | 4 | 2016 | 3481 | 0.100 |
Why?
|
Patient Education as Topic | 1 | 2023 | 2334 | 0.100 |
Why?
|
Hyperaldosteronism | 1 | 2016 | 252 | 0.100 |
Why?
|
Pancreaticoduodenectomy | 1 | 2016 | 512 | 0.100 |
Why?
|
Thoracic Vertebrae | 1 | 2017 | 614 | 0.100 |
Why?
|
Cell Proliferation | 3 | 2022 | 10429 | 0.100 |
Why?
|
Postoperative Hemorrhage | 1 | 2016 | 413 | 0.100 |
Why?
|
Dendritic Cells | 1 | 2023 | 2747 | 0.100 |
Why?
|
Models, Theoretical | 3 | 2019 | 3564 | 0.100 |
Why?
|
Mice | 8 | 2023 | 81819 | 0.100 |
Why?
|
Predictive Value of Tests | 3 | 2024 | 15398 | 0.100 |
Why?
|
Aged, 80 and over | 11 | 2024 | 59489 | 0.100 |
Why?
|
Prospective Studies | 6 | 2021 | 54802 | 0.100 |
Why?
|
Antineoplastic Agents, Phytogenic | 1 | 2016 | 616 | 0.100 |
Why?
|
Electrodes | 3 | 2012 | 609 | 0.090 |
Why?
|
Echocardiography | 2 | 2022 | 5045 | 0.090 |
Why?
|
Documentation | 1 | 2018 | 916 | 0.090 |
Why?
|
Aldosterone | 1 | 2016 | 881 | 0.090 |
Why?
|
Sarcoma | 1 | 2002 | 1802 | 0.090 |
Why?
|
Computer Simulation | 4 | 2008 | 6255 | 0.090 |
Why?
|
Lung | 4 | 2023 | 10033 | 0.090 |
Why?
|
Tumor Burden | 1 | 2016 | 1885 | 0.090 |
Why?
|
Down-Regulation | 1 | 2017 | 2927 | 0.090 |
Why?
|
Particle Size | 1 | 2014 | 1631 | 0.080 |
Why?
|
Muscle, Skeletal | 1 | 2005 | 4958 | 0.080 |
Why?
|
Neoadjuvant Therapy | 1 | 2021 | 2895 | 0.080 |
Why?
|
Medical History Taking | 1 | 2013 | 777 | 0.080 |
Why?
|
Ultrasonography | 1 | 2023 | 5993 | 0.080 |
Why?
|
Cell Line, Tumor | 3 | 2016 | 17075 | 0.080 |
Why?
|
Learning | 1 | 2019 | 1755 | 0.080 |
Why?
|
Software | 1 | 2023 | 4462 | 0.080 |
Why?
|
Chi-Square Distribution | 3 | 2016 | 3432 | 0.080 |
Why?
|
Swine | 7 | 2016 | 5988 | 0.080 |
Why?
|
Young Adult | 5 | 2022 | 59889 | 0.080 |
Why?
|
Boston | 2 | 2019 | 9338 | 0.080 |
Why?
|
Artificial Intelligence | 1 | 2023 | 2659 | 0.080 |
Why?
|
Students, Medical | 1 | 2021 | 1959 | 0.070 |
Why?
|
Pulmonary Blastoma | 1 | 2008 | 43 | 0.070 |
Why?
|
Pilot Projects | 2 | 2020 | 8733 | 0.070 |
Why?
|
Hepatocytes | 1 | 2015 | 1247 | 0.070 |
Why?
|
Algorithms | 3 | 2023 | 14071 | 0.070 |
Why?
|
Reproducibility of Results | 2 | 2023 | 20124 | 0.070 |
Why?
|
Reoperation | 1 | 2018 | 4294 | 0.070 |
Why?
|
Stroke Volume | 1 | 2022 | 5596 | 0.070 |
Why?
|
Graft Survival | 1 | 2018 | 3890 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2017 | 2844 | 0.070 |
Why?
|
Injections, Intravenous | 3 | 2004 | 1377 | 0.070 |
Why?
|
Recurrence | 1 | 2020 | 8501 | 0.070 |
Why?
|
Physical Examination | 1 | 2013 | 1266 | 0.070 |
Why?
|
Preoperative Care | 2 | 2013 | 2267 | 0.070 |
Why?
|
MicroRNAs | 1 | 2023 | 3785 | 0.070 |
Why?
|
Medical Oncology | 1 | 2019 | 2339 | 0.070 |
Why?
|
Pain Measurement | 1 | 2017 | 3561 | 0.070 |
Why?
|
Immunohistochemistry | 3 | 2015 | 11022 | 0.070 |
Why?
|
Perfusion | 2 | 2008 | 1407 | 0.070 |
Why?
|
Ethanol | 2 | 2003 | 1323 | 0.070 |
Why?
|
Mice, Nude | 1 | 2013 | 3618 | 0.070 |
Why?
|
Activities of Daily Living | 1 | 2016 | 2415 | 0.070 |
Why?
|
Phosphorylation | 1 | 2017 | 8278 | 0.070 |
Why?
|
Spinal Cord Injuries | 1 | 2014 | 927 | 0.070 |
Why?
|
Mentors | 2 | 2022 | 671 | 0.060 |
Why?
|
Adenoma | 1 | 2016 | 2152 | 0.060 |
Why?
|
Quality Improvement | 2 | 2018 | 3853 | 0.060 |
Why?
|
Neovascularization, Pathologic | 1 | 2015 | 2631 | 0.060 |
Why?
|
Gene Expression | 1 | 2017 | 7584 | 0.060 |
Why?
|
Lumbar Vertebrae | 1 | 2014 | 1873 | 0.060 |
Why?
|
Injections, Intralesional | 1 | 2005 | 281 | 0.060 |
Why?
|
Attitude of Health Personnel | 1 | 2018 | 3925 | 0.060 |
Why?
|
Extracellular Fluid | 1 | 2005 | 165 | 0.050 |
Why?
|
Regression Analysis | 3 | 2016 | 6322 | 0.050 |
Why?
|
Bronchography | 1 | 2003 | 70 | 0.050 |
Why?
|
Pleural Neoplasms | 1 | 2008 | 581 | 0.050 |
Why?
|
Health Care Surveys | 2 | 2023 | 2424 | 0.050 |
Why?
|
Immunotherapy | 1 | 2019 | 4752 | 0.050 |
Why?
|
Lactates | 1 | 2024 | 398 | 0.050 |
Why?
|
Paclitaxel | 1 | 2010 | 1728 | 0.050 |
Why?
|
Lymphography | 1 | 2023 | 189 | 0.050 |
Why?
|
Pyruvic Acid | 1 | 2024 | 205 | 0.050 |
Why?
|
Prognosis | 2 | 2022 | 29922 | 0.050 |
Why?
|
Diagnostic Imaging | 1 | 2017 | 3529 | 0.050 |
Why?
|
Phosphofructokinase-2 | 1 | 2022 | 33 | 0.050 |
Why?
|
Brachial Artery | 1 | 2024 | 375 | 0.050 |
Why?
|
Systems Analysis | 1 | 2023 | 168 | 0.050 |
Why?
|
Radiography | 2 | 2012 | 6919 | 0.050 |
Why?
|
alpha-Fetoproteins | 1 | 2023 | 226 | 0.050 |
Why?
|
Bilirubin | 1 | 2024 | 439 | 0.050 |
Why?
|
Lymphatic System | 1 | 2023 | 250 | 0.050 |
Why?
|
Rabbits | 2 | 2005 | 4734 | 0.050 |
Why?
|
Hemostatics | 1 | 2024 | 247 | 0.050 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2005 | 647 | 0.050 |
Why?
|
Observer Variation | 1 | 2008 | 2615 | 0.050 |
Why?
|
Sodium Chloride | 1 | 2004 | 576 | 0.050 |
Why?
|
Patient Selection | 1 | 2013 | 4255 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2018 | 39193 | 0.050 |
Why?
|
Spectrometry, Fluorescence | 1 | 2003 | 697 | 0.050 |
Why?
|
Tissue Distribution | 1 | 2005 | 2266 | 0.050 |
Why?
|
Drug Synergism | 1 | 2005 | 1749 | 0.040 |
Why?
|
Absorptiometry, Photon | 1 | 2007 | 1707 | 0.040 |
Why?
|
Cyclosporine | 1 | 2003 | 778 | 0.040 |
Why?
|
Referral and Consultation | 1 | 2013 | 3615 | 0.040 |
Why?
|
Ultrasonic Therapy | 1 | 2002 | 216 | 0.040 |
Why?
|
Temperature | 2 | 2006 | 2226 | 0.040 |
Why?
|
Nanostructures | 1 | 2005 | 548 | 0.040 |
Why?
|
Vena Cava, Inferior | 1 | 2023 | 463 | 0.040 |
Why?
|
Hospitalization | 2 | 2017 | 10808 | 0.040 |
Why?
|
Tonsillar Neoplasms | 1 | 2000 | 49 | 0.040 |
Why?
|
Fluorouracil | 1 | 2005 | 1648 | 0.040 |
Why?
|
Administration, Cutaneous | 1 | 2002 | 715 | 0.040 |
Why?
|
Task Performance and Analysis | 1 | 2024 | 770 | 0.040 |
Why?
|
Anti-Infective Agents, Local | 1 | 2002 | 245 | 0.040 |
Why?
|
Hemorrhage | 2 | 2024 | 3461 | 0.040 |
Why?
|
Palatine Tonsil | 1 | 2000 | 193 | 0.040 |
Why?
|
Chest Tubes | 1 | 2020 | 153 | 0.040 |
Why?
|
Dilatation and Curettage | 1 | 2019 | 53 | 0.040 |
Why?
|
Contrast Media | 3 | 2022 | 5329 | 0.040 |
Why?
|
Cisplatin | 1 | 2005 | 1658 | 0.040 |
Why?
|
Video Recording | 1 | 2024 | 969 | 0.040 |
Why?
|
Niacinamide | 1 | 2021 | 419 | 0.040 |
Why?
|
Hemoptysis | 1 | 2020 | 150 | 0.040 |
Why?
|
Pleura | 1 | 2020 | 240 | 0.040 |
Why?
|
Fever | 1 | 2006 | 1603 | 0.040 |
Why?
|
Joint Commission on Accreditation of Healthcare Organizations | 1 | 2018 | 91 | 0.040 |
Why?
|
Multivariate Analysis | 3 | 2016 | 12056 | 0.040 |
Why?
|
Glycolysis | 1 | 2022 | 838 | 0.040 |
Why?
|
Forms and Records Control | 1 | 2019 | 158 | 0.040 |
Why?
|
United States | 3 | 2023 | 72903 | 0.040 |
Why?
|
Creatinine | 1 | 2024 | 1915 | 0.040 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2003 | 750 | 0.040 |
Why?
|
Credentialing | 1 | 2018 | 118 | 0.040 |
Why?
|
Phenylurea Compounds | 1 | 2021 | 536 | 0.040 |
Why?
|
Thorax | 1 | 2021 | 554 | 0.040 |
Why?
|
Skin Neoplasms | 1 | 2017 | 5849 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2017 | 7875 | 0.040 |
Why?
|
Risk Assessment | 3 | 2016 | 24282 | 0.040 |
Why?
|
Lactic Acid | 1 | 2022 | 1137 | 0.030 |
Why?
|
Feedback, Psychological | 1 | 2017 | 97 | 0.030 |
Why?
|
Cattle | 2 | 2016 | 3801 | 0.030 |
Why?
|
Immunity | 1 | 2022 | 1002 | 0.030 |
Why?
|
Sarcoma, Yoshida | 1 | 1986 | 11 | 0.030 |
Why?
|
Clinical Coding | 1 | 2018 | 190 | 0.030 |
Why?
|
Agar | 2 | 2006 | 51 | 0.030 |
Why?
|
Polyethylene Terephthalates | 1 | 1986 | 109 | 0.030 |
Why?
|
Neuroendocrine Tumors | 1 | 2002 | 654 | 0.030 |
Why?
|
Laser Therapy | 1 | 2002 | 1108 | 0.030 |
Why?
|
Biomedical Research | 1 | 2011 | 3458 | 0.030 |
Why?
|
Fluorescent Dyes | 1 | 2003 | 1930 | 0.030 |
Why?
|
Wounds and Injuries | 1 | 2008 | 2511 | 0.030 |
Why?
|
Career Choice | 1 | 2021 | 769 | 0.030 |
Why?
|
Apoptosis | 4 | 2013 | 9514 | 0.030 |
Why?
|
Florida | 1 | 2016 | 416 | 0.030 |
Why?
|
Linear Models | 1 | 2005 | 5876 | 0.030 |
Why?
|
Calcinosis | 1 | 2003 | 1479 | 0.030 |
Why?
|
Fertility | 1 | 2019 | 768 | 0.030 |
Why?
|
Ischemia | 1 | 2023 | 1909 | 0.030 |
Why?
|
Trachea | 1 | 2020 | 1085 | 0.030 |
Why?
|
Workflow | 1 | 2019 | 862 | 0.030 |
Why?
|
Disease-Free Survival | 2 | 2016 | 6832 | 0.030 |
Why?
|
Neoplasm Staging | 2 | 2023 | 11206 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2016 | 6499 | 0.030 |
Why?
|
Personal Satisfaction | 1 | 2018 | 641 | 0.030 |
Why?
|
Abortion, Induced | 1 | 2019 | 471 | 0.030 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2000 | 1376 | 0.030 |
Why?
|
Analysis of Variance | 2 | 2012 | 6203 | 0.030 |
Why?
|
Sulfur Hexafluoride | 1 | 2012 | 26 | 0.030 |
Why?
|
Chronic Disease | 1 | 2008 | 9347 | 0.030 |
Why?
|
Triiodobenzoic Acids | 1 | 2012 | 124 | 0.030 |
Why?
|
Sensitivity and Specificity | 1 | 2008 | 14652 | 0.030 |
Why?
|
Diagnosis, Differential | 1 | 2008 | 12976 | 0.030 |
Why?
|
Models, Biological | 1 | 2008 | 9443 | 0.020 |
Why?
|
Adolescent | 5 | 2016 | 88835 | 0.020 |
Why?
|
Iohexol | 1 | 2012 | 204 | 0.020 |
Why?
|
Phthalic Acids | 1 | 1986 | 484 | 0.020 |
Why?
|
Retreatment | 1 | 2012 | 598 | 0.020 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2011 | 11868 | 0.020 |
Why?
|
Mice, Inbred BALB C | 1 | 2019 | 6220 | 0.020 |
Why?
|
Radiography, Thoracic | 1 | 2017 | 1315 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2003 | 4209 | 0.020 |
Why?
|
Logistic Models | 2 | 2016 | 13266 | 0.020 |
Why?
|
Health Personnel | 1 | 2023 | 3390 | 0.020 |
Why?
|
Deoxyguanosine | 1 | 2010 | 96 | 0.020 |
Why?
|
ROC Curve | 1 | 2017 | 3620 | 0.020 |
Why?
|
Aldehydes | 1 | 2010 | 168 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2011 | 591 | 0.020 |
Why?
|
Phospholipids | 1 | 2012 | 776 | 0.020 |
Why?
|
Acetylcysteine | 1 | 2010 | 262 | 0.020 |
Why?
|
Thermography | 1 | 2008 | 62 | 0.020 |
Why?
|
Disability Evaluation | 1 | 2016 | 1820 | 0.020 |
Why?
|
Point-of-Care Systems | 1 | 2017 | 1217 | 0.020 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2005 | 8923 | 0.020 |
Why?
|
Survival Rate | 2 | 2012 | 12795 | 0.020 |
Why?
|
Caspase 3 | 1 | 2010 | 731 | 0.020 |
Why?
|
Biopsy, Needle | 1 | 2012 | 1628 | 0.020 |
Why?
|
Nephrectomy | 1 | 2012 | 927 | 0.020 |
Why?
|
Quality Indicators, Health Care | 1 | 2017 | 1806 | 0.020 |
Why?
|
Immunoenzyme Techniques | 1 | 2010 | 1701 | 0.020 |
Why?
|
Antihypertensive Agents | 1 | 2016 | 2033 | 0.020 |
Why?
|
Clinical Trials as Topic | 1 | 2002 | 8041 | 0.020 |
Why?
|
Computer Graphics | 1 | 2008 | 344 | 0.020 |
Why?
|
Staining and Labeling | 1 | 2010 | 1072 | 0.020 |
Why?
|
Cell Survival | 1 | 2016 | 5747 | 0.020 |
Why?
|
Finite Element Analysis | 1 | 2008 | 440 | 0.020 |
Why?
|
Tyrosine | 1 | 2010 | 1428 | 0.020 |
Why?
|
Medicare | 1 | 2023 | 6823 | 0.020 |
Why?
|
Mass Screening | 1 | 2000 | 5446 | 0.010 |
Why?
|
Odds Ratio | 1 | 2016 | 9649 | 0.010 |
Why?
|
Adrenergic Agonists | 1 | 2004 | 55 | 0.010 |
Why?
|
Halothane | 1 | 2004 | 200 | 0.010 |
Why?
|
Arsenicals | 1 | 2004 | 117 | 0.010 |
Why?
|
Physician-Patient Relations | 1 | 2017 | 3278 | 0.010 |
Why?
|
Laser-Doppler Flowmetry | 1 | 2004 | 236 | 0.010 |
Why?
|
Calcium Oxalate | 1 | 2003 | 75 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 2 | 2008 | 4034 | 0.010 |
Why?
|
Survival Analysis | 1 | 2015 | 10070 | 0.010 |
Why?
|
Durapatite | 1 | 2003 | 166 | 0.010 |
Why?
|
Oxides | 1 | 2004 | 402 | 0.010 |
Why?
|
Academic Medical Centers | 1 | 2012 | 2780 | 0.010 |
Why?
|
Incidence | 1 | 2020 | 21480 | 0.010 |
Why?
|
Autoradiography | 1 | 2002 | 723 | 0.010 |
Why?
|
Surface-Active Agents | 1 | 2002 | 150 | 0.010 |
Why?
|
Cohort Studies | 2 | 2016 | 41649 | 0.010 |
Why?
|
Proportional Hazards Models | 1 | 2016 | 12509 | 0.010 |
Why?
|
Pneumonectomy | 1 | 2008 | 1128 | 0.010 |
Why?
|
Tonsillitis | 1 | 2000 | 28 | 0.010 |
Why?
|
Child | 3 | 2012 | 80564 | 0.010 |
Why?
|
Pseudolymphoma | 1 | 2000 | 30 | 0.010 |
Why?
|
Databases, Factual | 1 | 2016 | 8067 | 0.010 |
Why?
|
Child, Preschool | 2 | 2000 | 42500 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2022 | 26318 | 0.010 |
Why?
|
Epinephrine | 1 | 2004 | 783 | 0.010 |
Why?
|
Regional Blood Flow | 1 | 2004 | 1478 | 0.010 |
Why?
|
DNA Damage | 1 | 2010 | 2457 | 0.010 |
Why?
|
Signal Processing, Computer-Assisted | 1 | 2007 | 1456 | 0.010 |
Why?
|
Pakistan | 1 | 2000 | 300 | 0.010 |
Why?
|
Histones | 1 | 2010 | 2584 | 0.010 |
Why?
|
Body Temperature Regulation | 1 | 2001 | 292 | 0.010 |
Why?
|
Pulmonary Embolism | 1 | 2012 | 2598 | 0.010 |
Why?
|
Anesthetics, Inhalation | 1 | 2004 | 573 | 0.010 |
Why?
|
Oxidative Stress | 1 | 2010 | 3141 | 0.010 |
Why?
|
Body Composition | 1 | 2008 | 2439 | 0.010 |
Why?
|
Radiometry | 1 | 2003 | 804 | 0.010 |
Why?
|
Pregnancy | 1 | 2019 | 30260 | 0.010 |
Why?
|
Infusions, Intravenous | 1 | 2002 | 2229 | 0.010 |
Why?
|
Hypertension | 1 | 2016 | 8626 | 0.010 |
Why?
|
Models, Animal | 1 | 2002 | 2120 | 0.010 |
Why?
|
Disease Progression | 1 | 2012 | 13632 | 0.010 |
Why?
|
Medical Records | 1 | 2000 | 1409 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2012 | 22223 | 0.010 |
Why?
|
Tumor Cells, Cultured | 1 | 2002 | 6113 | 0.010 |
Why?
|
Carcinoma | 1 | 2004 | 2312 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2001 | 10729 | 0.000 |
Why?
|
Cost-Benefit Analysis | 1 | 2000 | 5526 | 0.000 |
Why?
|
Genetic Predisposition to Disease | 1 | 2008 | 18071 | 0.000 |
Why?
|
Infant | 1 | 2008 | 36386 | 0.000 |
Why?
|